Alpha Cognition Stock Price, News & Analysis

Alpha Cognition (Nasdaq: ACOG) announced that its partner China Medical System Holdings Limited (CMS) has received acceptance of the New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by China's National Medical Products Administration (NMPA) for review. The application is for treating mild-to-moderate Alzheimer's dementia.

The company stands to receive regulatory and sales milestones, plus royalties upon ZUNVEYL's approval in China and other Asian territories. According to Lancet Public Health, there are approximately 7.93 million patients with mild-to-moderate Alzheimer's dementia in China, with numbers expected to rise due to aging population trends.

Alpha Cognition (Nasdaq: ACOG) announced it will present new clinical data for its Alzheimer's treatment ZUNVEYL® at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada.

The company will present three poster presentations focusing on ZUNVEYL's bioequivalence to galantamine hydrobromide in different conditions and its dose proportionality. The presentations will showcase data from studies examining doses ranging from 5 to 15 milligrams under various conditions, including fed and fasting states.

Alpha Cognition (Nasdaq: ACOG) announced positive preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), particularly focusing on blast trauma injuries relevant to military personnel. The study, supported by the US Department of Defense and conducted with VA investigators, demonstrated significant therapeutic potential.

The research revealed that ALPHA-1062 reduced three toxic forms of brain protein Tau: pTau 217 (linked to long-term cognitive decline risk), pTau-S202/T205 (present in early-stage Alzheimer's pathology), and pTau 231 (elevated in early Alzheimer's and TBI). Additionally, high-dose ALPHA-1062 showed positive effects by reducing neuroinflammation markers and increasing nerve growth factor receptor expression.

The company's next steps include completing formulation of ALPHA-1062 for sublingual administration and conducting a bridging pharmacokinetic study comparing it to ZUNVEYL® and an existing intranasal formulation.

Alpha Cognition (NASDAQ: ACOG) has successfully launched its product ZUNVEYL(R) (benzgalantamine) in the U.S. long-term care (LTC) market on March 17, 2025. The launch has shown positive early results with strong clinician and patient feedback, successful patient outcomes, and robust ordering momentum. The company secured Medicare reimbursement post-launch, enhancing patient access in LTC settings. Additionally, ACOG obtained a new composition of matter patent for the tablet formulation of benzgalantamine in the U.S.

Financial highlights include ZUNVEYL net product revenues of $0.35M and licensing revenue of $2.6M. Management confirmed that all launch objectives remain on track and within budget, with commercial execution proceeding according to plan.

Alpha Cognition (NASDAQ: ACOG) reported its Q1 2025 financial results, highlighting the successful launch of ZUNVEYL (benzgalantamine) in the US long-term care market on March 17, 2025. The company secured $2.6M in licensing revenues from its partnership with CMS Pharma and reported initial ZUNVEYL product revenues of $347,000.

The company's net loss decreased to $2.0M from $5.0M in the same period last year. Cash position stands at $45.5M as of March 31, 2025, providing an estimated two-year runway. The company strengthened its intellectual property portfolio with a new composition patent extending ZUNVEYL's US protection through 2044.

Alpha Cognition (NASDAQ: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, will release its Q1 2025 financial results on May 15, 2025 after market close. The company will host a conference call to discuss the results and provide an operating overview on the same day at 4:30 PM ET.

Investors can participate in the conference call using the dial-in numbers 1-877-407-9039 or 1-201-689-8470. A Call me™ feature is available to avoid operator wait times, and participants can access the live audio webcast through the provided links. A replay will be available via webcast or by calling 1-844-512-2921 or 1-412-317-6671 with Access ID: 13753070.

Alpha Cognition (NASDAQ: ACOG) has announced its upcoming participation in the D. Boral Capital Inaugural Global Conference. The event is scheduled for May 14, 2025, at The Plaza Hotel in New York City.

Company CEO Michael McFadden will be available for one-on-one meetings throughout the conference day from 9:00 A.M. to 3:00 P.M. (ET). Interested parties who wish to schedule meetings with the management team can make arrangements by contacting John Perez at jperez@dboralcapital.com.

This conference participation represents an opportunity for investors and stakeholders to engage directly with Alpha Cognition's leadership and learn more about the company's developments and strategies.

Alpha Cognition (NASDAQ: ACOG) announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, showcasing clinical data for ZUNVEYL (benzgalantamine). The presentations will focus on bioequivalence studies that were important for the drug's FDA approval in July 2024 and commercial launch in March 2025.

ZUNVEYL, a twice-daily treatment for mild-to-moderate Alzheimer's disease, targets the long-term care market valued at $2 billion annually in the United States. The drug enhances cholinergic function to support memory, learning, and cognitive function. The company will present data on bioequivalence to Galantamine ER and IR, along with dose proportionality studies across the 5-15 mg range.

Alpha Cognition (NASDAQ: ACOG) demonstrated significant growth in 2024, successfully raising $52.8 million and completing its NASDAQ uplisting. The company achieved several key milestones, including completing commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), securing a U.S. patent extending protection through 2044, and finalizing phase one of a Department of Defense-funded study for head trauma treatment.

Notable achievements include a successful launch in the U.S. Long-Term Care (LTC) market, estimated at $2 billion, and securing a $44 million licensing agreement for Asia. The company reports positive initial physician feedback and is actively building international partnerships to diversify revenue streams.